Non-small cell lung cancer is the most common form of lung cancer. Surgical treatment may not be possible for various reasons. According to the current treatment standard, a multi-stage therapy is planned in such cases. This consists of simultaneous treatment with chemotherapy and radiotherapy (= radiation treatment), followed by immunotherapy. However, patients are often unable to receive radiochemotherapy in full and have to discontinue it prematurely due to side effects.
Aim of the study
Because some patients do not receive immunotherapy due to the stress caused by radiochemotherapy, this study aims to test whether shortening the duration of radiotherapy treatment and reducing the area irradiated will result in more patients completing the planned radiochemotherapy and then being able to receive the subsequent immunotherapy.
Who can take part?
Patients with advanced non-small cell lung cancer for whom surgical treatment is not possible. The tumor has an increased amount of the protein PD-L1.
Procedure
In our study, the participants are randomly divided into two groups in a 1:1 ratio (experimental group or control group). Each group receives a different type of radiation. You will receive concomitant chemotherapy and subsequent immunotherapy according to your trial center's routine. It is planned that all patients will be followed up until the entire study is completed.
Compensation
None
Original study name
FDG-PET based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO)
BASEC number
2023-02008
Financial support from
TheraOP gGmbH